| Title |
Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, January 2017
|
| DOI | 10.2147/tcrm.s121804 |
| Pubmed ID | |
| Authors |
Guntram Schernthaner, Sarah Jarvis, Chaim Lotan, Martin Prázný, Christoph Wanner, Thomas C Wascher |
| Abstract |
Diabetes is a global health emergency projected to affect 642 million people by 2040. Type 2 diabetes (T2D) represents 90% of diabetes cases and is associated with a range of cardiovascular (CV) risk factors that are more than double the incidence of CV disease and significantly increase mortality rates. Diabetes treatments have typically focused on improving glycemic control but their effect on CV outcomes has remained uncertain. In 2008, the US Food and Drug Administration (FDA) looked to address this knowledge gap and mandated CV outcome trials (CVOTs) for all new antidiabetic therapies. In 2015, EMPA-REG OUTCOME(®) became the first CVOT to present results for a sodium/glucose cotransporter 2 (SGLT2; also known as SLC5A2) inhibitor, empagliflozin. Subsequently, a regional meeting of the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D) brought together a respected faculty of international experts and 150 physicians from 14 countries to discuss the current unmet medical needs of patients with T2D, the results from the EMPA-REG OUTCOME study and the implications of these results for clinical practice. This article summarizes the current scientific evidence and the discussions that took place at the ACROSS T2D regional meeting, which was held in Vienna, Austria, on May 30, 2016. |
X Demographics
The data shown below were collected from the profiles of 57 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 7 | 12% |
| United States | 5 | 9% |
| Colombia | 3 | 5% |
| Philippines | 2 | 4% |
| Saudi Arabia | 2 | 4% |
| Argentina | 2 | 4% |
| Canada | 2 | 4% |
| United Kingdom | 2 | 4% |
| India | 2 | 4% |
| Other | 7 | 12% |
| Unknown | 23 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 36 | 63% |
| Practitioners (doctors, other healthcare professionals) | 10 | 18% |
| Scientists | 10 | 18% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 40 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 17% |
| Researcher | 6 | 15% |
| Student > Master | 6 | 15% |
| Student > Bachelor | 5 | 12% |
| Student > Doctoral Student | 3 | 7% |
| Other | 6 | 15% |
| Unknown | 8 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 54% |
| Psychology | 3 | 7% |
| Nursing and Health Professions | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 10 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 November 2018.
All research outputs
#1,187,201
of 25,628,260 outputs
Outputs from Therapeutics and Clinical Risk Management
#46
of 1,321 outputs
Outputs of similar age
#24,168
of 423,245 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#1
of 14 outputs
Altmetric has tracked 25,628,260 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,321 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,245 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.